---
document_datetime: 2025-12-29 09:46:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/firmagon.html
document_name: firmagon.html
version: success
processing_time: 0.1312003
conversion_datetime: 2025-12-31 03:30:48.304854
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Firmagon

[RSS](/en/individual-human-medicine.xml/65838)

##### Authorised

This medicine is authorised for use in the European Union

degarelix Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Firmagon](#news-on)
- [More information on Firmagon](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Firmagon is a medicine used to treat cancer of the prostate (a gland of the male reproductive system) in adult men when the cancer is 'hormone-dependent', which means that it responds to treatments that reduce the levels of the hormone testosterone. It is used:

• to treat advanced hormone-dependent prostate cancer. 'Advanced' means that the cancer has spread beyond the pelvis to nearby tissues such as lymph nodes and bone;

• before or together with radiotherapy to treat high-risk localised or locally advanced hormone-dependent prostate cancer. 'High-risk localised' means that the cancer is likely to spread beyond the prostate gland to nearby tissues and become 'locally advanced'.

Firmagon contains the active substance degarelix.

Expand section

Collapse section

## How is Firmagon used?

Firmagon is injected under the skin of the abdomen. Treatment starts with two 120-mg injections, followed by single 80-mg injections every month. Doctors should monitor the effectiveness of Firmagon treatment by looking at blood levels of testosterone and prostate-specific antigen (PSA). PSA is a protein that is produced by the prostate gland and is often found at high levels in men with prostate cancer.

The medicine can only be obtained with a prescription. For more information about using Firmagon, see the package leaflet or contact your doctor or pharmacist.

## How does Firmagon work?

Testosterone can make prostate cancer cells grow. The active substance in Firmagon, degarelix, reduces the amount of testosterone in the body by blocking the effects of a natural hormone called gonadotrophin-releasing hormone (GnRH). GnRH is the first step in a system responsible for testosterone production. By blocking GnRH, Firmagon slows down the growth of the cancer cells. When injected, Firmagon forms a gel under the skin that releases the active substance slowly over a few weeks.

## What benefits of Firmagon have been shown in studies?

A main study involving 610 men with prostate cancer at all stages of the disease showed that Firmagon is effective at reducing the amount of testosterone to levels seen in men whose testicles have been surgically removed.

In this study, Firmagon was as effective as leuprorelin (another medicine for prostate cancer). During the first year, 97% of the patients receiving Firmagon at the approved dose of 80 mg once a month dose had testosterone levels below the required level. This was compared with 96% of patients receiving leuprorelin.

A second study involving 244 men with intermediate- to high-risk prostate cancer found that Firmagon was as effective at reducing the prostate volume before radiotherapy as a combination of two other prostate cancer medicines, goserelin and bicalutamide. After 12 weeks of treatment, prostate volume decreased by 36.0% in patients treated with Firmagon and 35.3% in those receiving goserelin and bicalutamide.

## What are the risks associated with Firmagon?

The most common side effects with Firmagon (which may affect more than 1 in 10 people) are hot flushes and reactions at the injection site such as pain and redness.

For the full list of side effects and restrictions of Firmagon, see the package leaflet.

## Why is Firmagon authorised in the EU?

The European Medicines Agency decided that Firmagon's benefits are greater than its risks and it can be authorised for use in the EU.

Firmagon was as effective as leuprorelin in the treatment of advanced hormone-dependent prostate cancer. In addition, Firmagon was also effective for high-risk localised or locally advanced prostate cancer before radiotherapy. Based on its mechanism of action, the Agency considered that Firmagon can also be expected to be effective for high-risk localised or locally advanced prostate cancer in combination with radiotherapy. This will be further confirmed in an ongoing study.The agency also noted that treatment with Firmagon does not trigger the temporary sharp rise in testosterone levels seen with 'GnRH agonists' (other medicines for prostate cancer that stimulate the production of GnRH). This means that patients do not need to take other medicines to block testosterone at the start of treatment.

## What measures are being taken to ensure the safe and effective use of Firmagon?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Firmagon have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Firmagon are continuously monitored. Side effects reported with Firmagon are carefully evaluated and any necessary action taken to protect patients.

## Other information about Firmagon

Firmagon received a marketing authorisation valid throughout the EU on 17 February 2009.

Firmagon : EPAR - Medicine overview

Reference Number: EMA/435238/2020

English (EN) (144.42 KB - PDF)

**First published:** 04/03/2009

**Last updated:** 03/11/2021

[View](/en/documents/overview/firmagon-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-66)

български (BG) (165.76 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/bg/documents/overview/firmagon-epar-medicine-overview_bg.pdf)

español (ES) (146.93 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/es/documents/overview/firmagon-epar-medicine-overview_es.pdf)

čeština (CS) (165.94 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/cs/documents/overview/firmagon-epar-medicine-overview_cs.pdf)

dansk (DA) (141.3 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/da/documents/overview/firmagon-epar-medicine-overview_da.pdf)

Deutsch (DE) (144.79 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/de/documents/overview/firmagon-epar-medicine-overview_de.pdf)

eesti keel (ET) (120.13 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/et/documents/overview/firmagon-epar-medicine-overview_et.pdf)

ελληνικά (EL) (157.13 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/el/documents/overview/firmagon-epar-medicine-overview_el.pdf)

français (FR) (142.95 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/fr/documents/overview/firmagon-epar-medicine-overview_fr.pdf)

hrvatski (HR) (163.37 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/hr/documents/overview/firmagon-epar-medicine-overview_hr.pdf)

italiano (IT) (141.43 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/it/documents/overview/firmagon-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (173.24 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/lv/documents/overview/firmagon-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (164.28 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/lt/documents/overview/firmagon-epar-medicine-overview_lt.pdf)

magyar (HU) (163.08 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/hu/documents/overview/firmagon-epar-medicine-overview_hu.pdf)

Malti (MT) (167.44 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/mt/documents/overview/firmagon-epar-medicine-overview_mt.pdf)

Nederlands (NL) (142.41 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/nl/documents/overview/firmagon-epar-medicine-overview_nl.pdf)

polski (PL) (167.23 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/pl/documents/overview/firmagon-epar-medicine-overview_pl.pdf)

português (PT) (143 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/pt/documents/overview/firmagon-epar-medicine-overview_pt.pdf)

română (RO) (163.59 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/ro/documents/overview/firmagon-epar-medicine-overview_ro.pdf)

slovenčina (SK) (165.08 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/sk/documents/overview/firmagon-epar-medicine-overview_sk.pdf)

slovenščina (SL) (161.61 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/sl/documents/overview/firmagon-epar-medicine-overview_sl.pdf)

Suomi (FI) (139.9 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/fi/documents/overview/firmagon-epar-medicine-overview_fi.pdf)

svenska (SV) (140.3 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

03/11/2021

[View](/sv/documents/overview/firmagon-epar-medicine-overview_sv.pdf)

Firmagon - Risk-management-plan summary

English (EN) (89.72 KB - PDF)

**First published:** 24/07/2020

[View](/en/documents/rmp-summary/firmagon-risk-management-plan-summary_en.pdf)

## Product information

Firmagon : EPAR - Product Information

English (EN) (492.88 KB - PDF)

**First published:** 11/08/2008

**Last updated:** 30/03/2022

[View](/en/documents/product-information/firmagon-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-834)

български (BG) (578.52 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/bg/documents/product-information/firmagon-epar-product-information_bg.pdf)

español (ES) (651.11 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/es/documents/product-information/firmagon-epar-product-information_es.pdf)

čeština (CS) (742.6 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/cs/documents/product-information/firmagon-epar-product-information_cs.pdf)

dansk (DA) (442.86 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/da/documents/product-information/firmagon-epar-product-information_da.pdf)

Deutsch (DE) (516.65 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/de/documents/product-information/firmagon-epar-product-information_de.pdf)

eesti keel (ET) (653.92 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/et/documents/product-information/firmagon-epar-product-information_et.pdf)

ελληνικά (EL) (495.33 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/el/documents/product-information/firmagon-epar-product-information_el.pdf)

français (FR) (670.3 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/fr/documents/product-information/firmagon-epar-product-information_fr.pdf)

hrvatski (HR) (685.98 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/hr/documents/product-information/firmagon-epar-product-information_hr.pdf)

íslenska (IS) (533.63 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/is/documents/product-information/firmagon-epar-product-information_is.pdf)

italiano (IT) (536.87 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/it/documents/product-information/firmagon-epar-product-information_it.pdf)

latviešu valoda (LV) (723.49 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/lv/documents/product-information/firmagon-epar-product-information_lv.pdf)

lietuvių kalba (LT) (560.57 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/lt/documents/product-information/firmagon-epar-product-information_lt.pdf)

magyar (HU) (725.38 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/hu/documents/product-information/firmagon-epar-product-information_hu.pdf)

Malti (MT) (740.63 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/mt/documents/product-information/firmagon-epar-product-information_mt.pdf)

Nederlands (NL) (571.71 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/nl/documents/product-information/firmagon-epar-product-information_nl.pdf)

norsk (NO) (543.29 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/no/documents/product-information/firmagon-epar-product-information_no.pdf)

polski (PL) (881.21 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/pl/documents/product-information/firmagon-epar-product-information_pl.pdf)

português (PT) (627.47 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/pt/documents/product-information/firmagon-epar-product-information_pt.pdf)

română (RO) (601.47 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/ro/documents/product-information/firmagon-epar-product-information_ro.pdf)

slovenčina (SK) (816.12 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/sk/documents/product-information/firmagon-epar-product-information_sk.pdf)

slovenščina (SL) (693.99 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/sl/documents/product-information/firmagon-epar-product-information_sl.pdf)

Suomi (FI) (642.18 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/fi/documents/product-information/firmagon-epar-product-information_fi.pdf)

svenska (SV) (597.88 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

30/03/2022

[View](/sv/documents/product-information/firmagon-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0041 30/03/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Firmagon : EPAR - All Authorised presentations

English (EN) (17.28 KB - PDF)

**First published:** 04/03/2009

**Last updated:** 04/10/2022

[View](/en/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-194)

български (BG) (73.41 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/bg/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.5 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/es/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_es.pdf)

čeština (CS) (67.49 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/cs/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.91 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/da/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.4 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/de/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.2 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/et/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.98 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/el/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_el.pdf)

français (FR) (20.46 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/fr/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.12 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/hr/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.54 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/is/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_is.pdf)

italiano (IT) (20.29 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/it/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.21 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/lv/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.9 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/lt/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (63.16 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/hu/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (71.1 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/mt/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.11 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/nl/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (15.23 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/no/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_no.pdf)

polski (PL) (44.27 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/pl/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.43 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/pt/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_pt.pdf)

română (RO) (68.84 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/ro/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (70.82 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/sk/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (37.35 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/sl/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.69 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/fi/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.92 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/10/2022

[View](/sv/documents/all-authorised-presentations/firmagon-epar-all-authorised-presentations_sv.pdf)

Firmagon : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (32.94 KB - PDF)

**First published:** 04/03/2009

**Last updated:** 04/03/2009

[View](/en/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (21)](#file-language-dropdown-578)

български (BG) (117.01 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/bg/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (33.24 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/es/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (126.7 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/cs/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (38.97 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/da/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (38.87 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/de/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (32.96 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/et/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (126.67 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/el/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (38.66 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/fr/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

italiano (IT) (33.09 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/it/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (124.24 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/lv/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (128.49 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/lt/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (78.93 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/hu/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (125.85 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/mt/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (76.73 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/nl/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

polski (PL) (127.18 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/pl/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (34.79 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/pt/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (121.36 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/ro/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (123.32 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/sk/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (117.75 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/sl/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (34.62 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/fi/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (38.12 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

04/03/2009

[View](/sv/documents/conditions-member-states/firmagon-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Firmagon Active substance degarelix International non-proprietary name (INN) or common name degarelix Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code L02BX02

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated:

- for treatment of adult male patients with advanced hormone-dependent prostate cancer.

- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

- as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

## Authorisation details

EMA product number EMEA/H/C/000986 Marketing authorisation holder

Ferring Pharmaceuticals A/S

Amager Strandvej 405

Marketing authorisation issued 17/02/2009 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Firmagon : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (169.81 KB - PDF)

**First published:** 11/08/2009

**Last updated:** 30/03/2022

[View](/en/documents/procedural-steps-after/firmagon-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Firmagon-H-C-000986-II-0039-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/613173/2021

English (EN) (1.78 MB - PDF)

**First published:** 03/11/2021

[View](/en/documents/variation-report/firmagon-h-c-000986-ii-0039-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Firmagon (II-39-G)

Adopted

Reference Number: EMA/CHMP/498649/2021

English (EN) (148.58 KB - PDF)

**First published:** 17/09/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-firmagon-ii-39-g_en.pdf)

Firmagon-H-C-PSUSA-00000944-201902: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/617518/2019

English (EN) (163.32 KB - PDF)

**First published:** 10/01/2020

[View](/en/documents/scientific-conclusion/firmagon-h-c-psusa-00000944-201902-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Firmagon-H-C-986-PSUV-23 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/29520/2015

English (EN) (62.75 KB - PDF)

**First published:** 22/01/2015

**Last updated:** 22/01/2015

[View](/en/documents/scientific-conclusion/firmagon-h-c-986-psuv-23-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Firmagon-H-C-986-PSUV-20 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/729431/2013

English (EN) (68.52 KB - PDF)

**First published:** 04/12/2013

**Last updated:** 04/12/2013

[View](/en/documents/scientific-conclusion/firmagon-h-c-986-psuv-20-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Firmagon : EPAR - Public assessment report

English (EN) (889.16 KB - PDF)

**First published:** 04/03/2009

**Last updated:** 04/03/2009

[View](/en/documents/assessment-report/firmagon-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use summary of positive opinion for Firmagon

Reference Number: EMEA/CHMP/667162/2008

English (EN) (75.85 KB - PDF)

**First published:** 18/12/2008

**Last updated:** 18/12/2008

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-firmagon_en.pdf)

#### News on Firmagon

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021) 17/09/2021

#### More information on Firmagon

- [Use of degarelix among patients with prostate cancer in daily practice - post-authorisation study](https://catalogues.ema.europa.eu/study/28608)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/10/2022

## Share this page

[Back to top](#main-content)